Description du projet
Révolutionner le processus de production des substituts carnés
La demande croissante de viande, conjuguée aux efforts de réduction des émissions totales de CO2 générées par le bétail, a stimulé les recherches pour des solutions biotechniques à des fins de production de viande. L’une des principales pratiques adoptées pour relever ce défi est la production de viande à base de culture cellulaire (CCM pour «cell-cultured meat»), que l’on obtient en faisant croître des cellules de viande à partir d’un petit échantillon de cellules souches prélevées sur l’animal. Le projet CCMeat, financé par l’UE, introduira un ensemble de facteurs de croissance innovants, abordables et sans endotoxine, spécialement conçus pour la filière de la CCM. Grâce à sa technologie innovante, CCMeat vise à aider les producteurs de CCM à commercialiser leurs substituts carnés et à contribuer à réduire les conséquences délétères de la production de viande traditionnelle.
Objectif
ORF Genetics is a female-lead plant biotechnology company biofarming protein in barley for use in medical research, stem cell technology and skincare. Since 2001, we have produced over 50 proteins, specializing in human growth factors (GFs) which regulate the growth and development of cells. Our main focus has been on GFs for skincare use and now with our team of over 80 qualified scientists, researchers, marketers and more, we are aiming at a larger market, the cell-cultured meat (CCM) industry. The CCMeat project removes the biggest hurdle CCM producers are facing to bring their alternative meat products to market. With innovations in our technology we will produce affordable, endotoxin-free growth factors designed specifically for CCM: the MESOkine™ line (patent to be filed in June 2020). This will be done by scaling cultivation from our 2000m2 state-of-the-art geothermally powered greenhouse in Iceland to in-field cultivation sites. We will also introduce a protein processing technology (patent to be filed in July 2020) that will substantially decrease production costs and lead to greater GF yields. By 2030, our MESOkine™ line will drop GF prices from 3000€/kg of cultured meat to approximately 0.7€/kg meat at scales necessary to produce over 7 million tonnes of meat. We are already providing samples to CCM customers and expect to reach a 40% market share within 5 years with our strong first mover advantage. MESOkine™ sales are expected to rise exponentially and reach profitability of €19 million by 2026. As the demand for meat continues to grow, this innovation will have a profound impact on our planet, enabling CCM to avert many of the negative consequences of conventional meat production. This includes reducing greenhouse gases by more than 250 million tonnes of CO2-eq emissions, deforestation by producing 7-52 times as much meat with one hectare of land, and antibiotic resistance by sparing over 1000 tonnes of livestock antibiotic use.
Champ scientifique
- natural sciencesbiological sciencesbiochemistrybiomoleculesproteins
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibiotics
- agricultural sciencesanimal and dairy sciencedomestic animalsanimal husbandry
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance
Programme(s)
Régime de financement
SME-2 - SME instrument phase 2Coordinateur
IS-203 KOPAVOGUR
Islande
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.